These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 10776081)

  • 1. Intravenous iron products.
    Johnson CA; Mason NA; Bailie GR
    ANNA J; 1999 Oct; 26(5):522-4. PubMed ID: 10776081
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of sodium ferric gluconate complex in iron-deficient pediatric hemodialysis patients.
    Kaskel FJ
    Nat Clin Pract Nephrol; 2006 May; 2(5):244-5. PubMed ID: 16932433
    [No Abstract]   [Full Text] [Related]  

  • 3. Effectiveness of oral and intravenous iron therapy in haemodialysis patients.
    Jenq CC; Tian YC; Wu HH; Hsu PY; Huang JY; Chen YC; Fang JT; Yang CW
    Int J Clin Pract; 2008 Mar; 62(3):416-22. PubMed ID: 17511797
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safe administration of iron sucrose in a patient with a previous hypersensitivity reaction to ferric gluconate.
    Sane R; Baribeault D; Rosenberg CL
    Pharmacotherapy; 2007 Apr; 27(4):613-5. PubMed ID: 17381390
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acute injury with intravenous iron and concerns regarding long-term safety.
    Bishu K; Agarwal R
    Clin J Am Soc Nephrol; 2006 Sep; 1 Suppl 1():S19-23. PubMed ID: 17699372
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Review of available intravenous iron preparations in hemodialysis.
    Palmer K; Cameron K; Battistella M
    CANNT J; 2013; 23(2):51-4; quiz 55-6. PubMed ID: 24069699
    [No Abstract]   [Full Text] [Related]  

  • 7. Oral or intravenous iron for anemia correction in chronic kidney disease?
    Drüeke TB; Massy ZA
    Kidney Int; 2015 Oct; 88(4):673-5. PubMed ID: 26422625
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IV iron use in patients with higher serum ferritin: case study on anemia in kidney disease.
    Larson K
    Nephrol Nurs J; 2008; 35(2):184-93; quiz 194-5. PubMed ID: 18472686
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Parenteral iron use in the management of anemia in end-stage renal disease patients.
    Bailie GR; Johnson CA; Mason NA
    Am J Kidney Dis; 2000 Jan; 35(1):1-12. PubMed ID: 10620537
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of intravenous iron supplementation in chronic kidney disease: an update.
    Macdougall IC; Geisser P
    Iran J Kidney Dis; 2013 Jan; 7(1):9-22. PubMed ID: 23314137
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of iron sucrose in patients sensitive to iron dextran: North American clinical trial.
    Van Wyck DB; Cavallo G; Spinowitz BS; Adhikarla R; Gagnon S; Charytan C; Levin N
    Am J Kidney Dis; 2000 Jul; 36(1):88-97. PubMed ID: 10873877
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravenous iron sucrose versus oral iron ferrous sulfate for antenatal and postpartum iron deficiency anemia: a randomized trial.
    Froessler B; Cocchiaro C; Saadat-Gilani K; Hodyl N; Dekker G
    J Matern Fetal Neonatal Med; 2013 May; 26(7):654-9. PubMed ID: 23130909
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Letter to the editor: treatment of iron deficiency anemia.
    Ozsoylu S
    Pediatr Hematol Oncol; 2005; 22(7):645-6; author reply 647-8. PubMed ID: 16166057
    [No Abstract]   [Full Text] [Related]  

  • 14. A randomized trial of intravenous and oral iron in chronic kidney disease.
    Agarwal R; Kusek JW; Pappas MK
    Kidney Int; 2015 Oct; 88(4):905-14. PubMed ID: 26083656
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravenous iron supplementation for the treatment of the anemia of moderate to severe chronic renal failure patients not receiving dialysis.
    Silverberg DS; Iaina A; Peer G; Kaplan E; Levi BA; Frank N; Steinbruch S; Blum M
    Am J Kidney Dis; 1996 Feb; 27(2):234-8. PubMed ID: 8659499
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sodium ferric gluconate complex in sucrose: safer intravenous iron therapy than iron dextrans.
    Faich G; Strobos J
    Am J Kidney Dis; 1999 Mar; 33(3):464-70. PubMed ID: 10070910
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting Iron Deficiency Anemia in Heart Failure.
    Saraon T; Katz SD
    Prog Cardiovasc Dis; 2016; 58(4):407-15. PubMed ID: 26657161
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Addressing patient concerns about intravenous iron therapy.
    Robbins KC
    Nephrol Nurs J; 2003 Apr; 30(2):220-4, 258. PubMed ID: 12737000
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Iron isomaltoside 1000: a new intravenous iron for treating iron deficiency in chronic kidney disease.
    Wikström B; Bhandari S; Barany P; Kalra PA; Ladefoged S; Wilske J; Thomsen LL
    J Nephrol; 2011; 24(5):589-96. PubMed ID: 21240875
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Slow intravenous iron administration does not aggravate oxidative stress and inflammatory biomarkers during hemodialysis: a comparative study between iron sucrose and iron dextran.
    Malindretos P; Sarafidis PA; Rudenco I; Raptis V; Makedou K; Makedou A; Grekas DM
    Am J Nephrol; 2007; 27(6):572-9. PubMed ID: 17804904
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.